Alaunos Therapeutics Inc. stocks have been trading up by 29.04 percent following bullish sentiment on its clinical progress.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Alaunos Therapeutics completed its deal for Velaris Therapeutics, adding a new cardiopulmonary pipeline built around ActRII-Fc ligand traps and related biologics.
- The company raised about $350M in a concurrent private placement, expected to fund TCRT operations into 2029 and key proof‑of‑concept and regulatory milestones.
- Proceeds are earmarked to advance lead candidate VLR199 for pulmonary arterial hypertension, a serious and often fatal cardiopulmonary disease.
- Following the acquisition and financing news, TCRT shares spiked, with reports citing gains of roughly 126% to about 225% on extremely heavy trading volume.
- The $350M was raised via Series C non‑voting convertible preferred stock, a structure traders should track for future dilution risk.
Live Update At 07:46:49 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 29.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT just flipped from sleepy biotech to hot momentum name. The daily chart shows Alaunos Therapeutics grinding around $0.75–$1.25 for weeks, then detonating on 2026/10/13. That day, TCRT opened at $1.73, ripped to $4.32, dipped to $1.51, and closed at $3.03. That is a massive range and a huge shift in market perception.
Intraday, the 5‑minute candles tell the same story. Pre‑market trading around $3.20–$3.70 turned into sharp swings above $4.00, with TCRT repeatedly spiking and pulling back but holding a much higher base than prior days. For active traders, that’s classic “news plus volume” momentum.
More Breaking News
- AMC Stock Rises As New App, Debt Deal Shift Trading Focus
- JBLU Stock Slides As Wall Street Slashes Price Targets
- JOBY Stock Slides As Barclays Downgrade Rattles eVTOL Hopes
- Intel Stock Drops As Terafab Talks Pivot Toward TSMC
Under the hood, Alaunos Therapeutics is still an early‑stage biotech. Latest quarterly numbers show only $5,000 in revenue and a pretax margin around -3,300%, with negative earnings and free cash flow of about -$300,000. Returns on assets and equity are deeply negative, and the current ratio under 1.0 signals a weak standalone balance sheet. That’s why the roughly $350M private placement and extended runway to 2029 matter so much for TCRT traders.
Why Traders Are Watching TCRT Now
TCRT went from a niche oncology player to a cardiopulmonary story overnight. By closing the Velaris Therapeutics acquisition, Alaunos Therapeutics picked up a pipeline of ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. That’s a different narrative, and the market clearly liked it.
The real power move is the paired financing. Alaunos Therapeutics locked in about $350M via a private placement of Series C non‑voting convertible preferred stock. Management says this should fund operations into 2029 and push several candidates, including lead asset VLR199, through proof‑of‑concept and initial regulatory filings. For a micro‑cap like TCRT, removing near‑term financing overhang is a big deal.
Traders saw that in real time. One report flagged Alaunos Therapeutics stock jumping about 126% on the news. Another cited roughly 225% upside on extremely heavy volume. That kind of rip tells you two things: shorts were likely caught leaning the wrong way, and momentum funds rushed in once TCRT broke out of its sub‑$1 channel.
But experienced traders also recognize the trade‑offs. Series C non‑voting convertible preferred stock usually brings future dilution once converted. The price action in TCRT is telling you the crowd is willing to look past that — for now — in exchange for several years of cash runway and fresh cardiopulmonary catalysts. For short‑term trading, that translates into big intraday ranges, clean technical levels, and a news‑driven story everyone is suddenly watching.
Conclusion
For active traders, TCRT is now a textbook news catalyst play. Alaunos Therapeutics closed a transformative deal with Velaris Therapeutics, secured about $350M in fresh cash, and reset its story around VLR199 and a broader cardiopulmonary pipeline. The market’s response — a 100%‑plus to roughly 225% surge on massive volume — confirms that TCRT has captured attention far beyond its usual biotech niche.
That doesn’t change the fundamentals overnight. Alaunos Therapeutics is still pre‑commercial, with tiny revenue, ugly margins, and negative returns. The cash from the private placement buys time through 2029, but TCRT still has to deliver clinical data and regulatory progress to justify a higher long‑term valuation. Traders also need to respect the overhang from those Series C non‑voting convertible preferred shares, which can weigh on the common stock down the road.
In this kind of setup, process matters. As Tim Sykes likes to say, “I don’t trade the company, I trade the pattern.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. TCRT now offers a clear pattern: a violent news‑driven breakout after a major acquisition and financing, followed by elevated liquidity and volatility. Traders studying Alaunos Therapeutics should focus on support and resistance, volume fades, and how price reacts to any follow‑up updates — always with a plan to cut losses fast if the hype unwinds.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.